Drug Type Small molecule drug |
Synonyms Doxorubicin hyaluronan acid, Doxorubicin hyaluronic acid, HA-doxorubicin + [4] |
Target |
Action inhibitors |
Mechanism DNA intercalators, Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H30ClNO11 |
InChIKeyMWWSFMDVAYGXBV-RUELKSSGSA-N |
CAS Registry25316-40-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Phase 2 | - | - | |
| Cardiotoxicity drug-induced | Preclinical | Australia | 01 May 2007 |





